|
News
-
06.27.2023IAM Patent 1000 Recognizes Perkins Coie and 51 Lawyers as Patent Leaders in U.S. and AsiaPress ReleasesPerkins Coie is pleased to announce that 51 of its intellectual property (IP) lawyers in the United States and Asia were recognized by Intellectual Asset Management (IAM) in the 2023 IAM Patent 1000 list.
-
06.01.2023Perkins Coie Named Among Top Law Firms in 2023 Chambers USAPress ReleasesPerkins Coie is proud to announce that it has again been ranked by Chambers & Partners, publishers of Chambers USA: America’s Leading Lawyers for Business, as one of the top law firms in the United States.
-
8.10.2022IAM Patent 1000 Recognizes Perkins Coie and 49 Firm Attorneys as Patent Leaders in U.S. and ChinaPress ReleasesPerkins Coie is pleased to announce that 49 of its intellectual property (IP) attorneys in the United States and Asia were recognized by Intellectual Asset Management (IAM) in the 2022 IAM Patent 1000 list, which recognizes the world’s leading, best-in-class patent professionals in patent prosecution, licensing, and litigation. The firm was also ranked nationally in the United States and China and internationally overall for patent litigation, prosecution, and post-grant proceedings.
-
07.06.2022Perkins Coie Recognized as IP and Life Sciences Leader in US and China by Managing IPPress ReleasesPerkins Coie is pleased to announce that it has again been ranked nationally in Managing Intellectual Property’s IP Stars guide, achieving recognition in five categories in 2022: Patent Contentious, Patent Prosecution, PTAB Litigation, Trademark Prosecution, and Life Sciences.
-
06.01.2022Perkins Coie Named Among Top Law Firms in 2022 Chambers USAPress ReleasesPerkins Coie is proud to announce that it has again been ranked by Chambers & Partners, publishers of Chambers USA: America’s Leading Lawyers for Business, as one of the top law firms in the United States.
-
06.22.2021Perkins Coie Recognized as National Patent, Trademark, and Life Sciences Leader by Managing IPPress ReleasesPerkins Coie is pleased to announce that it has again been ranked nationally in Managing Intellectual Property’s IP Stars guide, achieving 2021 recognition in five categories: Patent Contentious, Patent Prosecution, PTAB Litigation, Trademark Prosecution, and Life Sciences.
-
05.20.2021Perkins Coie Named Among Top Law Firms in 2021 Chambers USAPress ReleasesPerkins Coie is proud to announce that it has again been ranked by Chambers & Partners, publishers of Chambers USA: America’s Leading Lawyers for Business, as one of the top law firms in the United States.
-
07.02.2020Perkins Coie Recognized as National Patent and Life Sciences Leader by Managing IPPress ReleasesPerkins Coie is pleased to announce that it has again been ranked nationally in Managing Intellectual Property’s 2020 IP Stars guide in the Patent Contentious, Patent Prosecution, PTAB Litigation, and Life Sciences: IP categories.
-
09.24.2019Perkins Coie Honored with Case of the Year and Top Litigator Awards by LMG Life SciencesPress ReleasesPerkins Coie is pleased to announce that the firm, Intellectual Property Co-Chair Shannon Bloodworth and Intellectual Property Partner David Anstaett have been recognized for their work in the life sciences industry by the LMG Life Sciences Awards, an annual ranking of leading North American law firms and lawyers specializing in the industry.
-
04.17.2019Perkins Coie Attorneys in the Madison Office Recognized by the State Bar of Wisconsin Regarding Their Pro Bono ContributionsGeneral News
The attorneys in the Madison office of Perkins Coie LLP are recognized for their outstanding pro bono contributions. The 24 attorneys in the firm’s Madison office contributed 1,962 hours of pro bono time in 2018.
-
10.12.2018Perkins Coie Attorneys Mentioned in Law360 - Fed. Circ. Rules Teva's Copaxone Patents Are InvalidGeneral NewsDavid Anstaett, Shannon Bloodworth, Brandon White, Dan Bagatell, and Christina Jordan McCullough were mentioned in the Law360* article, "Fed. Circ. Rules Teva's Copaxone Patents Are Invalid," as representation for Mylan Pharmaceuticals Inc. Bloomberg also covered the decision in the article, "Teva Loses Appeal Over Four Patents for MS Drug Copaxone."
*Subscription-based publication -
10.12.2018Perkins Coie Client Win Reported by Mylan - Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate CourtGeneral NewsPerkins Coie represented Mylan in its recent milestone Federal Circuit wins, relating to Glatiramer Acetate Injection 40mg/mL. The decision was reported in the Mylan article, "Mylan Prevails in Copaxone® 40mg/mL Litigation Against Teva in U.S. Appellate Court."
-
04.24.2018Perkins Coie Attorneys Noted as Counsel in the Law.com Article - Skilled in the Art: Forget Oil States. It's Time to Get SAS-syGeneral News
Law.com
Perkins Coie was noted as counsel in the Law.com article, "Skilled in the Art: Forget Oil States. It's Time to Get SAS-sy," which discusses a slew of pharma companies challenging dosing patents. -
04.13.2017Several Perkins Coie Attorneys Mentioned in Law360's Weekly Verdict: Legal Lions & LambsGeneral News
Law360
Several Perkins Coie attorneys were mentioned in the article "Law360's Weekly Verdict: Legal Lions & Lambs," published by Law360. -
05.19.2014Anesthesia Applicator Device Wins Perkins Coie's $10,000 Award at University of Wisconsin-Madison 2014 Innovative Minds ChallengePress ReleasesSELA, a novel anesthesia applicator, won Perkins Coie’s $10,000 Innovative Minds Award on May 9 at the University of Wisconsin-Madison (UW-Madison).
